These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3408240)

  • 21. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Intraduodenal infusion of levodopa].
    Valldeoriola F; Cámara A
    Rev Neurol; 2010 Jul; 51(1):41-8. PubMed ID: 20568067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility.
    Kurlan R; Rothfield KP; Woodward WR; Nutt JG; Miller C; Lichter D; Shoulson I
    Neurology; 1988 Mar; 38(3):419-21. PubMed ID: 3126408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease.
    Syed N; Murphy J; Zimmerman T; Mark MH; Sage JI
    Mov Disord; 1998 Mar; 13(2):336-8. PubMed ID: 9539350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
    Pahwa R; Marjama J; McGuire D; Lyons K; Zwiebel F; Silverstein P; Ward R; Koller WC
    Mov Disord; 1996 Jul; 11(4):427-30. PubMed ID: 8813223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
    Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duodenal levodopa infusion for the treatment of Parkinson's disease.
    Samanta J; Hauser RA
    Expert Opin Pharmacother; 2007 Apr; 8(5):657-64. PubMed ID: 17376020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
    Muhlack S; Woitalla D; Welnic J; Twiehaus S; Przuntek H; Müller T
    Neurosci Lett; 2004 Jun; 363(3):284-7. PubMed ID: 15182961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlled release levodopa in Parkinson's disease: influence of selection criteria and conversion recommendations in the clinical outcome of 450 patients. STAR Study Group.
    Linazasoro G; Grandas F; Martínez Martín P; Bravo JL
    Clin Neuropharmacol; 1999; 22(2):74-9. PubMed ID: 10202601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
    Nutt JG; Carter JH; Woodward W; Hammerstad JP; Gancher ST
    Mov Disord; 1993 Apr; 8(2):139-43. PubMed ID: 8474479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
    Mouradian MM; Juncos JL; Fabbrini G; Chase TN
    Ann Neurol; 1987 Oct; 22(4):475-9. PubMed ID: 3435068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.
    Antonini A; Tolosa E
    Expert Rev Neurother; 2009 Jun; 9(6):859-67. PubMed ID: 19496689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
    Nyholm D; Lewander T; Johansson A; Lewitt PA; Lundqvist C; Aquilonius SM
    Clin Neuropharmacol; 2008; 31(2):63-73. PubMed ID: 18382177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
    Nutt JG; Woodward WR; Anderson JL
    Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical experience in switching patients from standard levodopa to a controlled-release levodopa].
    Leiva Santana C; Galvañ Berenguer B; Gómez García J; Cabello López J
    Neurologia; 1996 Jan; 11(1):1-9. PubMed ID: 8714169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease.
    Bredberg E; Nilsson D; Johansson K; Aquilonius SM; Johnels B; Nyström C; Paalzow L
    Eur J Clin Pharmacol; 1993; 45(2):117-22. PubMed ID: 8223831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nutt JG
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.
    Deleu D; Ebinger G; Michotte Y
    Eur J Clin Pharmacol; 1991; 41(5):453-8. PubMed ID: 1761073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.